TD Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$61.6M Sell
680,527
-62,285
-8% -$5.22M 0.05% 263
2026
Q1
$59.5M Sell
742,812
-35,317
-5% -$2.91M 0.05% 278
2025
Q4
$66.3M Buy
778,129
+47,051
+6% +$3.86M 0.05% 259
2025
Q3
$56.9M Sell
731,078
-12,562
-2% -$982K 0.05% 294
2025
Q2
$58.2M Sell
743,640
-167,546
-18% -$12.5M 0.05% 282
2025
Q1
$66M Sell
911,186
-93,165
-9% -$6.67M 0.06% 264
2024
Q4
$74.4M Sell
1,004,351
-80,362
-7% -$5.62M 0.07% 244
2024
Q3
$72.2M Sell
1,084,713
-330,152
-23% -$24M 0.06% 259
2024
Q2
$131M Sell
1,414,865
-48,443
-3% -$4.29M 0.12% 158
2024
Q1
$140M Buy
1,463,308
+139,697
+11% +$11.7M 0.13% 159
2023
Q4
$101M Buy
1,323,611
+645,204
+95% +$44.9M 0.1% 179
2023
Q3
$47M Buy
678,407
+108,904
+19% +$8.75M 0.06% 261
2023
Q2
$53.7M Sell
569,503
-27,020
-5% -$2.35M 0.06% 245
2023
Q1
$49.4M Sell
596,523
-3,570
-0.6% -$281K 0.06% 254
2022
Q4
$44.8M Buy
600,093
+223,128
+59% +$17.2M 0.06% 275
2022
Q3
$31.6M Buy
376,965
+5,473
+1% +$527K 0.04% 324
2022
Q2
$35.3M Sell
371,492
-7,833
-2% -$811K 0.04% 321
2022
Q1
$44.7M Buy
379,325
+1,064
+0.3% +$119K 0.04% 310
2021
Q4
$49M Sell
378,261
-18,390
-5% -$2.15M 0.04% 332
2021
Q3
$44.9M Sell
396,651
-2,057
-0.5% -$235K 0.05% 303
2021
Q2
$44.8M Sell
398,708
-13,029
-3% -$1.23M 0.05% 313
2021
Q1
$34.4M Buy
411,737
+32,459
+9% +$2.74M 0.04% 352
2020
Q4
$34.6M Buy
379,278
+2,449
+0.6% +$203K 0.04% 323
2020
Q3
$30.1M Buy
376,829
+144,979
+63% +$11.3M 0.04% 308
2020
Q2
$16M Sell
231,850
-3,386
-1% -$241K 0.02% 404
2020
Q1
$14.8M Buy
235,236
+13,383
+6% +$965K 0.03% 386
2019
Q4
$17.3M Sell
221,853
-19,764
-8% -$1.54M 0.03% 415
2019
Q3
$17.7M Sell
241,617
-9,081
-4% -$638K 0.03% 387
2019
Q2
$15.4M Sell
250,698
-6,165
-2% -$373K 0.02% 416
2019
Q1
$16.4M Sell
256,863
-5,145
-2% -$294K 0.03% 400
2018
Q4
$13.4M Buy
262,008
+8,685
+3% +$439K 0.02% 422
2018
Q3
$14.7M Buy
253,323
+6,438
+3% +$315K 0.02% 452
2018
Q2
$12M Buy
246,885
+6,984
+3% +$326K 0.02% 486
2018
Q1
$11.2M Sell
239,901
-2,934
-1% -$127K 0.02% 495
2017
Q4
$9.12M Buy
242,835
+3,606
+2% +$132K 0.01% 543
2017
Q3
$8.72M Sell
239,229
-11,532
-5% -$440K 0.01% 541
2017
Q2
$9.88M Sell
250,761
-4,893
-2% -$179K 0.02% 526
2017
Q1
$8.02M Sell
255,654
-4,263
-2% -$133K 0.01% 585
2016
Q4
$8.12M Sell
259,917
-45,861
-15% -$1.49M 0.01% 564
2016
Q3
$12.3M Sell
305,778
-13,398
-4% -$505K 0.02% 472
2016
Q2
$10.6M Buy
319,176
+9,534
+3% +$326K 0.02% 498
2016
Q1
$9.1M Sell
309,642
-10,362
-3% -$286K 0.02% 520
2015
Q4
$8.43M Buy
320,004
+4,200
+1% +$109K 0.02% 522
2015
Q3
$7.48M Sell
315,804
-87,000
-22% -$2.1M 0.01% 528
2015
Q2
$9.56M Sell
402,804
-88,398
-18% -$1.99M 0.02% 520
2015
Q1
$11.7M Buy
491,202
+160,542
+49% +$3.6M 0.02% 459
2014
Q4
$7.02M Sell
330,660
-28,128
-8% -$565K 0.01% 586
2014
Q3
$6.11M Buy
358,788
+28,956
+9% +$457K 0.01% 589
2014
Q2
$4.72M Sell
329,832
-24,000
-7% -$325K 0.01% 665
2014
Q1
$4.37M Sell
353,832
-21,000
-6% -$242K 0.01% 677
2013
Q4
$4.11M Sell
374,832
-35,400
-9% -$399K 0.01% 685
2013
Q3
$4.76M Sell
410,232
-334,200
-45% -$3.91M 0.01% 616
2013
Q2
$8.34M Buy
+744,432
New +$8.81M 0.02% 450

Other funds holding EW

TD Asset Management's EW Position: Q2 2026 in Review

TD Asset Management reduced its Edwards Lifesciences (EW) stake by 8.4% in Q2 2026, selling an estimated $5.22M and leaving 680,527 shares worth $61.6M. The position accounts for 0.05% of the portfolio, ranked #263.

TD Asset Management first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $140M in Q1 2024. 1,086 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • TD Asset Management held 680,527 shares of Edwards Lifesciences worth $61.6M as of Q2 2026.
  • TD Asset Management sold 62,285 Edwards Lifesciences shares in Q2 2026, an estimated $5.22M.
  • Edwards Lifesciences made up 0.05% of TD Asset Management's portfolio in Q2 2026, its #263 holding.
  • TD Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • TD Asset Management's Edwards Lifesciences position peaked at $140M in Q1 2024.
  • 1,086 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.